NRX Pharmaceuticals, Inc. financial data

Symbol
NRXP, NRXPW on Nasdaq
Industry
Pharmaceutical Preparations
Location
1201 Orange Street, Suite 600, Wilmington, DE
State of incorporation
DE
Fiscal year end
December 31
Former names
Big Rock Partners Acquisition Corp. (to 5/24/2021)
Latest financial report
10-K - Q4 2024 - Mar 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 74.1 %
Debt-to-equity -123 % +68.9%
Return On Equity 133 % -76.8%
Return On Assets -586 % -201%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 16.9M shares -82.3%
Common Stock, Shares, Outstanding 14.6M shares +73.9%
Entity Public Float 21.5M USD -27.6%
Common Stock, Value, Issued 15K USD +87.5%
Weighted Average Number of Shares Outstanding, Basic 10.6M shares +40.5%
Weighted Average Number of Shares Outstanding, Diluted 8.85M shares +33.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 6.2M USD -53.6%
General and Administrative Expense 13.5M USD -5%
Operating Income (Loss) -18.5M USD +33.5%
Nonoperating Income (Expense) -6.62M USD -186%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -25.1M USD +16.7%
Earnings Per Share, Basic -2.36 USD/shares +40.7%
Earnings Per Share, Diluted -0.74 USD/shares +55.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.44M USD -68.6%
Other Assets, Current 128K USD
Assets, Current 3.3M USD -52%
Other Assets, Noncurrent 349K USD -19%
Assets 3.65M USD -50.1%
Accounts Payable, Current 4.13M USD -10.8%
Employee-related Liabilities, Current 577K USD -30.9%
Accrued Liabilities, Current 5.3M USD +4.79%
Liabilities, Current 21.9M USD +14.8%
Liabilities 26.9M USD +41.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -278M USD -9.93%
Stockholders' Equity Attributable to Parent -23.2M USD -97.9%
Liabilities and Equity 3.65M USD -50.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.67M USD +39.7%
Net Cash Provided by (Used in) Financing Activities 395K USD -84.5%
Net Cash Provided by (Used in) Investing Activities -4K USD -33.3%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 14.6M shares +73.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.32M USD -92%
Interest Paid, Excluding Capitalized Interest, Operating Activities 374K USD
Deferred Tax Assets, Valuation Allowance 49.7M USD +10.6%
Deferred Tax Assets, Gross 44.9M USD +6.78%
Depreciation 1K USD 0%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -1.63M USD +73.2%
Deferred Tax Assets, Operating Loss Carryforwards 39.8M USD +10.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 50M shares 0%
Additional Paid in Capital 255M USD +5.65%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 486K USD +25.6%
Interest Expense 230K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%